BRIEF-Arcus Biosciences And Summit Therapeutics Enter Into Clinical Trial Collaboration

Summit Therapeutics Inc
Arcus Biosciences, Inc.

Summit Therapeutics Inc

SMMT

0.00

Arcus Biosciences, Inc.

RCUS

0.00

July 22 (Reuters) - Arcus Biosciences Inc RCUS.N:

  • ARCUS BIOSCIENCES AND SUMMIT THERAPEUTICS ENTER INTO CLINICAL TRIAL COLLABORATION TO EVALUATE CASDATIFAN COMBINED WITH IVONESCIMAB IN KIDNEY CANCER

  • ARCUS BIOSCIENCES INC: UNDER TERMS OF AGREEMENT, SUMMIT WILL SUPPLY IVONESCIMAB AND ARCUS WILL CONDUCT AND SPONSOR COMBINATION STUDY

  • ARCUS BIOSCIENCES INC: BOTH COS WILL CONTRIBUTE TO COST OF STUDY, EACH CO WILL RETAIN DEVELOPMENT & COMMERCIAL RIGHTS TO THEIR RESPECTIVE MOLECULES

  • ARCUS BIOSCIENCES INC: INITIAL DATA FROM THIS CLINICAL TRIAL COLLABORATION IS EXPECTED TO BE GENERATED BY MID-2027

Source text: ID:nBw5cyfqKa

Further company coverage: RCUS.N


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.